UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2016
Commission File Number: 001-37423
Biotie Therapies Oyj
(Exact name of registrant as specified in its charter)
Biotie Therapies Corp.
(Translation of registrant’s name into English)
Joukahaisenkatu 6, FI-20520
Turku, Finland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | BIOTIE THERAPIES CORP. |
| | | |
| | | | By: | /s/ Kristian Rantala |
| | | | | Name: | Kristian Rantala |
| | | | | Title: | Chief Financial Officer |
Date: July 28, 2016
EXHIBIT INDEX
| Exhibit Number | Description |
| 99.1 | Stock Exchange Release dated July 28, 2016 (9:00 a.m. EET): Biotie Therapies Corp.’s Interim Report for the reporting period January 1 – June 30, 2016 |
| | |
